Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026Feb 19, 2026 6:30 AM Eastern Standard Time# Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026Share---PIOMBINO DESE, Italy--([BUSINESS WIRE])-- [Stevanato Group S.p.A.](NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issu ...

Core Insights - Stevanato Group S.p.A. will participate in two upcoming investor conferences, indicating its active engagement with investors and the market [1][9] - The company is a leading global provider of drug containment, drug delivery, and diagnostic solutions, serving the pharmaceutical, biotechnology, and life sciences industries [3][8] Upcoming Events - The company will attend the 7th Annual Wolfe Research Healthcare Conference in New York City on November 17, 2025, at 8:40 a.m. ET [5] - It will also participate in the Jefferies Global Healthcare Conference in London on November 19, 2025, at 11:00 a.m. GMT [5] Company Overview - Founded in 1949, Stevanato Group offers an integrated portfolio of products, processes, and services that address customer needs across the entire drug life cycle [3] - The company's core capabilities include scientific research and development, technical innovation, and engineering excellence, which are essential for providing value-added solutions to clients [3]

Core Points - Stevanato Group S.p.A. will report its financial results for the third quarter of 2025 on November 6, 2025, at 6:30 a.m. (ET) [1] - A conference call and webcast will be held on the same day at 8:30 a.m. (ET) to discuss the financial results, with a slide presentation available on the company's Investor Relations page [2] - Participants are encouraged to pre-register for the conference call to gain immediate access [3] Company Overview - Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries [4] - The company offers an integrated portfolio of products, processes, and services that address customer needs across the entire drug life cycle [4] - Stevanato Group emphasizes its core capabilities in scientific research and development, technical innovation, and engineering excellence [4]

Core Insights - TimesSquare Capital Management reported a gross return of 11.28% and a net return of 11.02% for its "U.S. Small Cap Growth Strategy" in Q2 2025, underperforming the Russell 2000 Growth Index which returned 11.97% [1] - The fund highlighted Stevanato Group S.p.A. (NYSE:STVN) as a key investment, noting its significant stock performance with a one-month return of 18.79% and a 52-week gain of 39.44% [2][3] Company Performance - Stevanato Group S.p.A. closed at $26.87 per share on September 11, 2025, with a market capitalization of $7.335 billion [2] - The company experienced a 20% stock increase following a strong first quarter performance, particularly in its Biopharmaceutical and Diagnostic Solutions segment, with stabilizing vial demand and reduced destocking [3] Investment Sentiment - Despite the positive outlook for Stevanato Group S.p.A., it was not among the 30 most popular stocks among hedge funds, with only 8 hedge fund portfolios holding the stock at the end of Q2 2025, down from 10 in the previous quarter [4] - The analysis suggests that while Stevanato Group S.p.A. has potential, certain AI stocks may offer greater upside potential and lower downside risk [4]